| Dr Brandon Mark Taylor, DO | |
|
4740 N Penngrove Way Ste 210, Meridian, ID 83646-7447 | |
| (208) 514-0203 | |
| Not Available |
| Full Name | Dr Brandon Mark Taylor |
|---|---|
| Gender | Male |
| Speciality | Pediatrics |
| Location | 4740 N Penngrove Way Ste 210, Meridian, Idaho |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1285855106 | NPI | - | NPPES |
| 36331415914 | Medicaid | NE |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208000000X | Pediatrics | O0725 (Idaho) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr Brandon Mark Taylor, DO 4740 N Penngrove Way Ste 210, Meridian, ID 83646-7447 Ph: (208) 514-0203 | Dr Brandon Mark Taylor, DO 4740 N Penngrove Way Ste 210, Meridian, ID 83646-7447 Ph: (208) 514-0203 |
News Archive
As a practicing internist, I need all the help I can get in diagnosing the many diseases that threaten the life and well-being of my patients. So perhaps you'll understand why I'm angered by the reckless new recommendations from the U.S. Preventive Services Task Force (a panel of primary care experts) that I don't use the prostate-specific antigen to screen men older than 40 for prostate cancer.
An analytical chemist at the Department of Energy's Pacific Northwest National Laboratory has been recognized with a National Institutes of Health Director's New Innovator Award. The award will support Wei-Jun Qian's drive to make new research and clinical diagnostic tools that are dramatically more sensitive, reliable and faster than current technologies.
ViroPharma Incorporated today announced the license of worldwide rights from Intellect Neurosciences, Inc. to its clinical stage drug candidate, OX1, being developed for the treatment of Friedreich's Ataxia (FA), a rare, hereditary, progressive neurodegenerative disease.
The Genome Institute of Singapore (GIS), an institute under the umbrella of the Agency for Science, Technology and Research, and Fluidigm Corporation today announced the establishment of the first research center in Asia exclusively dedicated to accelerating the understanding of how individual cells work, and how diagnosis and treatment might be enhanced through insight derived from single cells.
Omthera Pharmaceuticals, Inc., a privately-held emerging specialty pharmaceuticals company, announced today that the first patient has been dosed in its pivotal Phase III EVOLVE (EpanoVa fOr Lowering Very high triglyceridEs) trial for Epanova™, the Company's lead compound for the treatment of patients with very high triglycerides. Epanova is an Omega-3 fatty acid containing a novel formulation of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA).
› Verified 8 days ago
Kristina Miles, DO Pediatrics Medicare: Medicare Enrolled Practice Location: 3277 E Louise Dr Ste 200, Meridian, ID 83642 Phone: 208-463-3000 | |
Mrs. Anne E. Riffle, M.D. Pediatrics Medicare: Medicare Enrolled Practice Location: 3653 N. Locust Grove Road, Meridian, ID 83646 Phone: 208-338-5437 Fax: 208-939-9811 | |
Robert F Adams, MD Pediatrics Medicare: Medicare Enrolled Practice Location: 520 S Eagle Rd, Meridian, ID 83642 Phone: 208-336-9188 | |
Joshua Edwin Albright, Pediatrics Medicare: Medicare Enrolled Practice Location: 1620 S Celebration Ave, Meridian, ID 83642 Phone: 208-884-1030 | |
Lisa M. Barker, MD Pediatrics Medicare: Medicare Enrolled Practice Location: 1620 S Celebration Ave, Meridian, ID 83642 Phone: 208-884-1030 | |
Dr. Brian C Birch, MD Pediatrics Medicare: Medicare Enrolled Practice Location: 2921 S Meridian Rd, Meridian, ID 83642 Phone: 208-297-7847 Fax: 208-203-0097 | |
Susan C Kim, MD Pediatrics Medicare: Medicare Enrolled Practice Location: 3280 E Lanark Dr, Meridian, ID 83642 Phone: 208-377-4400 Fax: 208-377-4416 |